Dompé

Dompé is a mature, global biopharma company transitioning from a traditional pharmaceutical base to a biotech innovation leader. Its core asset is a proprietary recombinant human Nerve Growth Factor (rhNGF), with its first approved product, cenegermin (Oxervate), for neurotrophic keratitis. The company is advancing a pipeline of rhNGF-based therapies into new neurological and ophthalmology indications while commercializing its Exscalate AI/High-Performance Computing platform for external partnerships. With significant R&D investment and a commercial footprint in ~40 countries, Dompé blends deep therapeutic expertise with cutting-edge computational drug discovery.

Exscalate: A supercomputing-powered drug discovery platform combining a vast chemical library, high-performance computing (HPC), and AI/ML for virtual screening and molecular docking to accelerate drug discovery and repurposing.

In ophthalmology, Dompé's cenegermin is first-in-class for NK, but faces general competition in dry eye and inflammation. In neurology, it would be a pioneer if successful in cerebral palsy. Its Exscalate platform competes with numerous well-funded AI-drug discovery firms (e.g., Recursion, Exscientia) and internal big pharma efforts.